logo
Plus   Neg
Share
Email

Vectura Group Maintains FY Financial Guidance - Quick Facts

Vectura Group plc (VEC.L) said the Group has made a positive start to trading during first half 2019, with flutiform product supply revenues making an important contribution to growth. Vectura re-confirmed its financial guidance for 2019.

Regarding R&D investment priorities, Vectura said it will continue to focus on securing new partner contracts for the development of inhaled therapies. The Group will continue to invest in new proprietary platform technologies.

The Board of Vectura Group has approved, in principle, a capital return of approximately 50 million pounds, commencing in 2019. It is currently expected to be structured as a tender offer, although the Board continues to review other options.

Vectura will report its interim results on 10 September 2019.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration has granted accelerated approval to Tazverik for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Epithelioid sarcoma is a rare sub-type of soft... STIHL recalls about 16,400 STIHL RE 90 pressure washers due to injury hazard. According to the company, the recalled pressure washer nozzle can disconnect from the spray wand when under pressure during use, posing an injury hazard. STIHL said it received seven reports of the nozzle detaching from... CVS Health Corp. launched 13 new HealthHUB locations in CVS Pharmacy stores across Philadelphia and South New Jersey. The healthcare company said it developed the HealthHUB store format to help people manage chronic conditions more conveniently and affordably. The store also features health and wellness products, clinical services and expertise.
RELATED NEWS
Follow RTT
>